Epidemiology and Management of Cutaneous T-Cell Lymphoma at Hospital México, Costa Rica.
NCT07538960 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 350
Last updated 2026-04-20
Summary
Adult patients (≥18 years) with confirmed cutaneous T-cell lymphoma evaluated at Hospital México between 2019 and 2025 will be retrospectively analyzed using EDUS records to describe their epidemiological profile, clinical characteristics, treatments, and outcomes.
Conditions
- Cutaneous
- T-cell Lymphoma
- Lymph Node Cancer
Sponsors & Collaborators
-
Caja Costarricense de Seguro Social
lead OTHER_GOV
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-05-31
- Primary Completion
- 2027-05-31
- Completion
- 2027-05-31
Countries
- Costa Rica
Study Locations
More Related Trials
-
QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma
NCT04052061 ·Status: WITHDRAWN ·Phase: PHASE1
-
MB-105 in Patients With CD5 Positive T-cell Lymphoma
NCT06534060 ·Status: RECRUITING ·Phase: PHASE2
-
T-cell Brazil: Prospective Collection of Data in T-cell Lymphomas Patients
NCT03207789 ·Status: UNKNOWN
-
A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping
NCT02509598 ·Status: COMPLETED ·Phase: PHASE2
-
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
NCT01110733 ·Status: COMPLETED
-
Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old.
NCT00429065 ·Status: UNKNOWN
-
Identification of Prognostic Factors and New Therapeutic Targets in Cutaneous Lymphomas
NCT04520529 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Study of Adult T-Cell Leukemia/Lymphoma Among Carriers of HTLV-1
NCT00339638 ·Status: COMPLETED
-
Integrated Molecular and Clinical Profiling to Optimize Outcome Prediction in Splenic Marginal Zone Lymphoma
NCT02945319 ·Status: COMPLETED
-
Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma
NCT07477366 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
NCT05338931 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP
NCT00725231 ·Status: UNKNOWN ·Phase: PHASE3
-
A Retrospective Study of Clinical, Phenotypic and Genetic Factors of Peripheral T-Cell Lymphomas
NCT02788916 ·Status: COMPLETED
-
A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies
NCT07503353 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
A Registry for People With T-cell Lymphoma
NCT05978141 ·Status: RECRUITING
-
Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL)
NCT01553786 ·Status: COMPLETED ·Phase: PHASE2
-
Diagnostic Classifier for Cutaneous T-cell Lymphomas
NCT04491825 ·Status: UNKNOWN
-
Identification Predictive Markers of Immunochemotherapy Response to the Primary Cutaneous Diffuse Large B Cell Lymphoma
NCT04183569 ·Status: UNKNOWN
-
Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma
NCT05618925 ·Status: RECRUITING ·Phase: PHASE1
-
Local Registry of Primary Cutaneous T-cell Lymphomas
NCT07160023 ·Status: RECRUITING
-
Minimal Residual Disease in Peripheral T-cell Lymphoma
NCT03297697 ·Status: COMPLETED
-
Retrospective Analysis of Skin/Soft Tissue Primary NK/T Cell Lymphoma
NCT01341119 ·Status: COMPLETED
-
Long-term Outcomes Associated With Juvenile-onset Mycosis Fungoides and Lymphomatoid Papulosis
NCT06207812 ·Status: RECRUITING
-
Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma
NCT07125872 ·Status: RECRUITING ·Phase: PHASE2
-
Intercontinental Cooperative Non-Hodgkin T-cell Lymphoma Prospective Registry Study
NCT02691351 ·Status: COMPLETED